Composition: Each capsule contains Lansoprazole..30 mg Description: - Lansoprazole is the prototype member of a new class of substituted benzimidazoles, which inhibit the final common step in gastric acid secretion. The only significant pharmacological action of Lansoprazole is dose dependent suppression of gastric acid secretion; without anticholinergic or H2 blocking action. It is a powerful inhibitor of gastric acid: can totally abolish HCl secretion, both resting as well as that stimulated by any of the secretagogues, without much effect on pepsin, intrinsic factor, juice volume and gastric motility. Lansoprazole is inactive at neutral pH, but at pH<5 rearranges to two charged cationic forms (a sulphenic acid and a sulphenamide configurations) that react covalently with the SH groups of the H+K+ATPase enzyme and inactivate it irreversibly, specially when two molecules of Omeprazole react with one molecule of the enzyme. After diffusing into the parietal cell from blood it gets concentrated in the acidic pH are unable to diffuse back. Moreover it gets tightly bound to the enzyme. These features and the specific localization of H+K+ATPase to apical membrane of the parietal cells confer high degree of selectivity of action to Lansprazole. Acid secretion resumes only when new H+K+ATPase molecules are synthesized. It has higher oral bioavilability then omeprazole. Indications: - Use in peptic ulcer and hyperacidity problems. Reflux or ulcerative oesophagitis. Zollinger-Ellison syndrome. NSAIDS-induced ulcers. Dosage: - Gastric ulcer; 20 mg once daily for 8 weeks. Reflux oesophagitis; 20 mg once daily for 4 weeks Duodenal ulcer; 20 mg once daily for 4 weeks Zollinger-Ellison syndrome 60 ml once a day with maintenance dosage 80 mg in divided doses. Contra indications: - Hypersensitivity and neonates. Pediatrics: Not recommended Pregnancy: Safety not established. Lactation: Safety not established. Presentation: - 10x10 capsules in a Multicarton.